OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Results of Operations and Financial Condition
Item 9.01 Results of Operations and Financial Condition
Please see the disclosure set forth under Item 9.01, “Other Events,” of this Current Report on Form 8-K relating to the Company reaffirming previously communicated fourth quarter 2018 growth expectations, which is incorporated by reference into this Item 9.01.
Item 9.01 Other Events.
On January 6, 2019, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference (“J.P. Morgan”) on January 9, 2019, Oxford Immunotec Global PLC (the “Company”) issued a press release (the “Press Release”) announcing that its Board of Directors approved a share repurchase program, subject to shareholder approval, which would involve the repurchase of up to $100 million of the Company’s outstanding ordinary shares over a five-year period. If approved by the Company’s shareholders, share repurchases, if any, will be made in the open market or in any private transaction, from time-to-time and in accordance with applicable laws and regulations. The share repurchase program does not obligate the Company to repurchase any specific number of shares and may be suspended or terminated at any time without prior notice.
The Company also announced that during the Company’s public webcast presentation at J.P. Morgan, it will reaffirm previously communicated fourth quarter 2018 growth expectations.
A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. A live webcast of the presentation will be available online from the investor relations page of the Company’s website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 90 days.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Oxford Immunotec Global PLC Exhibit
EX-99.1 2 ex_132628.htm EXHIBIT 99.1 ex_132628.htm Exhibit 99.1 Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018 OXFORD,…
To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
